<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6063">
  <stage>Registered</stage>
  <submitdate>24/06/2016</submitdate>
  <approvaldate>24/06/2016</approvaldate>
  <nctid>NCT02815592</nctid>
  <trial_identification>
    <studytitle>Trial of BMS-986012 in Combination With Platinum and Etoposide</studytitle>
    <scientifictitle>A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001692-67</secondaryid>
    <secondaryid>CA001-044</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986012
Treatment: drugs - Cisplatin
Treatment: drugs - Etoposide
Treatment: drugs - Platinum
Treatment: drugs - Carboplatin

Experimental: Experimental Arm 1 - BMS-986012/Cisplatin/Etoposide

Experimental: Experimental Arm 2 - BMS-986012/Carboplatin/Etoposide

Experimental: Experimental Arm 3A - BMS-986012/Platinum/Etoposide

Active Comparator: Active Comparator Arm 3B - Platinum/Etoposide


Treatment: drugs: BMS-986012


Treatment: drugs: Cisplatin


Treatment: drugs: Etoposide


Treatment: drugs: Platinum


Treatment: drugs: Carboplatin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events (AEs)</outcome>
      <timepoint>Cycle 1, Day 1 up to approximately 26 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with serious adverse events (SAEs )</outcome>
      <timepoint>Date of enrollment up to approximately 26 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Discontinuations due to AEs</outcome>
      <timepoint>Cycle 1, Day 1 up to approximately 26 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants who died due to AEs</outcome>
      <timepoint>Cycle 1, Day 1 up to approximately 26 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with laboratory toxicity grade shift from baseline</outcome>
      <timepoint>Cycle 1, Day 1 up to approximately 26 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>From date of first dose or randomization until date of confirmed disease progression, up to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed serum concentration(Cmax)</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed serum concentration(Tmax)</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed serum concentration at the end of a dosing interval(Ctau)</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in 1 dosing interval(AUC(TAU))</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterization of Immunogenicity - Anti-Drug Antibodies</outcome>
      <timepoint>Cycle 1 Day 1 up to 60 days after last dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Male and Females 18 years of age or older

          -  Pulmonary SCLC documented by histology or cytology

          -  Extensive disease (Stage IV) SCLC

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior systemic therapy for lung cancer

          -  Symptomatic brain metastases

          -  Grade 2 peripheral neuropathy

          -  Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV), or hepatitis C virus (HCV

          -  Other active malignancies or prior malignancy within 2 years

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>11/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/10/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Local Institution - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda - Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this this study is to administer BMS-986012 in Combination with Platinum and
      Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02815592</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>